AstraZeneca is leaving no stone unturned in its effort to make baxdrostat the first aldosterone synthase inhibitor (ASI) to get approval for hard-to-treat hypertension. The FDA has now started a ...

These 250 companies and 40 leaders had an exceptional year, executing standout projects and initiatives that delivered meaningful results for their industries, customers, and future growth. See our ...